Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2022-10-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January-September 2022' and contains comprehensive financial statements, including revenue, expenses, and cash flow data for the Q3 and 9M periods. It also includes detailed management commentary, clinical pipeline updates, and operational highlights. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2022
2022-10-20 English
Hansa Biopharma: Ökning av antalet aktier och röster
Share Issue/Capital Change Classification · 98% confidence The document is a press release ("PRESSMEDDELANDE") dated September 30, 2022, announcing an increase in the number of shares and votes due to a new issue of 850,769 C-shares, authorized by the board based on a shareholder mandate from the AGM. This action directly relates to changes in the company's capital structure, specifically the issuance of new shares to cover incentive programs. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2022-09-30 Swedish
Hansa Biopharma: Increase of the number of shares and votes
Share Issue/Capital Change Classification · 98% confidence The document is a press release announcing a change in the company's share capital and the total number of outstanding shares and votes following a resolution by the board of directors to issue class C shares. This directly relates to changes in the company's capital structure, specifically the issuance of new shares. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific corporate action regarding equity.
2022-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding and voting rights for Hansa Biopharma AB, specifically reporting the number of shares held (2,598,012) and the resulting percentage of voting rights (0.57929%). This structure, focusing on the 'Before the transaction,' 'Transaction Date,' and 'After the transaction' holdings, is characteristic of a Major Shareholding Notification, where an investor reports crossing a specific threshold of ownership. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a director's dealing report (DIRS), but rather a notification of a significant change in ownership.
2022-09-15 English
Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
Transaction in Own Shares Classification · 99% confidence The document is a press release announcing a specific corporate action: the issuance and immediate repurchase of class C shares for the purpose of long-term incentive programs (Share Rights Program 2022 and Option Program 2022). This action directly relates to changes in the company's capital structure involving its own shares. Reviewing the definitions, 'Transaction in Own Shares (Code: POS)' covers the company buying back or selling its own shares (share repurchase/issuance). While 'Share Issue/Capital Change (SHA)' is related, POS is more specific to the mechanics described (issue and immediate repurchase/buyback). Since the core activity is the transaction involving the company's own shares for incentive purposes, POS is the most appropriate classification.
2022-09-09 English
Hansa Biopharma: Emission och återköp av C-aktier för incitamentsprogram
Transaction in Own Shares Classification · 99% confidence The document is a press release titled "Hansa Biopharma: Emission och återköp av C-aktier för incitamentsprogram" (Issuance and repurchase of C-shares for incentive program). It explicitly details the board's decision to issue and immediately repurchase a specific number of C-shares to fulfill obligations under various long-term incentive plans (share rights and options) approved by the AGM. This action directly relates to changes in the company's capital structure and the management of its share pool for employee compensation, which falls under the definition of Capital/Financing Update (CAP) or potentially Share Issue/Capital Change (SHA). Since the core action is the issuance and subsequent repurchase of shares related to incentive programs, 'Share Issue/Capital Change' (SHA) is the most precise fit, as it covers changes in capital structure via share issuance/repurchase, even if the ultimate goal is compensation fulfillment. The document length is short (2790 chars), but it is a substantive announcement of a corporate action, not just a notice that a report is available, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule.
2022-09-09 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.